Clinical and bacteriological efficacy of rifampin-streptomycin combination for two weeks followed by rifampin and clarithromycin for six weeks for treatment of Mycobacterium ulcerans disease.
about
Drugs for treating Buruli ulcer (Mycobacterium ulcerans disease)Mycolactone-Dependent Depletion of Endothelial Cell Thrombomodulin Is Strongly Associated with Fibrin Deposition in Buruli Ulcer LesionsMycobacterium ulcerans treatment--can antibiotic duration be reduced in selected patients?Efficacy of Rifampin Plus Clofazimine in a Murine Model of Mycobacterium ulcerans DiseaseSterilizing Activity of Fully Oral Intermittent Regimens against Mycobacterium Ulcerans Infection in MiceKinetics of mycolactone in human subcutaneous tissue during antibiotic therapy for Mycobacterium ulcerans diseaseTreatment Outcome of Patients with Buruli Ulcer Disease in Togo.Loop-Mediated Isothermal Amplification for Laboratory Confirmation of Buruli Ulcer Disease-Towards a Point-of-Care Test.In vitro antibacterial activity and in vivo efficacy of hydrated clays on Mycobacterium ulcerans growthAnalysis of Mycobacterium ulcerans-specific T-cell cytokines for diagnosis of Buruli ulcer disease and as potential indicator for disease progression.Local Heat Application for the Treatment of Buruli Ulcer: Results of a Phase II Open Label Single Center Non Comparative Clinical Trial.Epidemiology and management of Buruli ulcer.Antibiotic Complications During the Treatment of Mycobacterium ulcerans Disease in Australian Patients.Clinical outcomes of Ghanaian Buruli ulcer patients who defaulted from antimicrobial therapy.Mycobacterium ulcerans in the Daintree 2009-2015 and the mini-epidemic of 2011.Exploration of a standard treatment for Buruli ulcer through a comprehensive analysis of all cases diagnosed in Japan.In Silico Prediction of Antibiotic Resistance in Mycobacterium ulcerans Agy99 through Whole Genome Sequence Analysis.Increasing Experience with Primary Oral Medical Therapy for Mycobacterium ulcerans Disease in an Australian Cohort.Compliance with antimicrobial therapy for buruli ulcer.Wound healing: Natural history and risk factors for delay in Australian patients treated with antibiotics for Mycobacterium ulcerans disease.Adhesion of the ulcerative pathogen Mycobacterium ulcerans to DACC-coated dressings.Shorter-course treatment for Mycobacterium ulcerans disease with high-dose rifamycins and clofazimine in a mouse model of Buruli ulcerBuruli Ulcer: a Review of the Current Knowledge
P2860
Q24186073-C4C9209B-6913-49CA-90E7-1FBE8C043657Q27318699-E8CF5955-5645-4378-9199-30421993CACDQ28543227-E5C02002-1CE3-4899-874E-09543D04C24FQ28552524-3A9FB1B8-EF36-49B7-8F23-91EA673F716FQ28552736-D533EC23-3310-4EA7-82CD-6B408ABFAACFQ33613484-E3A0BB0A-8B86-48EB-9783-23AAB10F4E44Q35810457-E30218C1-8D97-462D-B7A6-720BF36B519EQ35840888-2D4B53E2-A51E-46EC-8EEB-3506908C3B51Q35911339-470F1FD8-ADDD-49D8-9017-B420B8546699Q36291527-6999E931-4348-4D5E-A415-2B60221F8ECAQ36446126-A2173C3E-F1A8-4148-B56D-7561F1E32BE1Q38219419-886E1FA9-7FC5-4658-9F72-B6BAE6E24637Q38741481-DB104535-EDD8-484E-BC69-B8B591156E0CQ38838051-EAC1E4EC-F670-404B-9AC9-B3571C03E7B7Q39225070-497D35C9-6D9B-4CD8-9604-F46A8D76CE9FQ39496473-CD9F1DB2-9B30-43A9-9890-715C034870F3Q40117191-3575390F-5501-485B-A295-AF3E29183EF2Q40789030-38C42CAA-0705-4B02-BB73-F646CDCAE5B2Q42932818-3964F726-2C4E-403E-B348-9FDF5B17EAABQ51738497-937A6AF4-BD63-41B7-8139-DE3E50A22182Q53469363-E1B68734-2BCA-4F46-8322-4A8E6567DE2DQ58785246-F5340BC2-30EB-41FB-A28A-43D593ABDC7DQ59132198-7EB10ABB-8468-484E-9E2E-949B35E75057
P2860
Clinical and bacteriological efficacy of rifampin-streptomycin combination for two weeks followed by rifampin and clarithromycin for six weeks for treatment of Mycobacterium ulcerans disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 09 December 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Clinical and bacteriological e ...... ycobacterium ulcerans disease.
@en
Clinical and bacteriological e ...... ycobacterium ulcerans disease.
@nl
type
label
Clinical and bacteriological e ...... ycobacterium ulcerans disease.
@en
Clinical and bacteriological e ...... ycobacterium ulcerans disease.
@nl
prefLabel
Clinical and bacteriological e ...... ycobacterium ulcerans disease.
@en
Clinical and bacteriological e ...... ycobacterium ulcerans disease.
@nl
P2093
P2860
P356
P1476
Clinical and bacteriological e ...... Mycobacterium ulcerans disease
@en
P2093
Fred S Sarfo
Justice Abotsi
Kingsley Asiedu
Mark Forson
Mark Wansbrough-Jones
Mohammed K Abass
Tuah Wilson
William Thompson
P2860
P304
P356
10.1128/AAC.02165-13
P407
P577
2013-12-09T00:00:00Z